PharmaShots | Incisive News in 3 Shots

Subscribe Now

Edgewise Therapeutics

Edgewise Therapeutics Reports First Patient Dosing in P-II Study of EDG-7500 to Treat Obstructive Hypertrophic Cardiomyopathy

Edgewise Therapeutics Reports First Patient Dosing in P-II Study of EDG-7500 to Treat Obstructive Hypertrophic Cardiomyopathy

May 7, 2024

Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy

Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy

October 14, 2022

Edgewise Therapeutics Reports 2-Month Interim Results of EDG-5506 in P-Ib (ARCH) Study for the Treatment of Becker Muscular Dystrophy

Edgewise Therapeutics Reports 2-Month Interim Results of EDG-5506 in P-Ib (ARCH) Study for the Treatment of Becker Muscular Dystro...

June 21, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us